Boundless Bio is a pioneering brand at the forefront of understanding and effectively treating the most challenging cancers. Our team of bold and dedicated innovators is transforming patient outcomes by focusing on oncogene amplified cancers. We have charted a new spatial map of the cancer genome within cancer cells, unlocking the potential of extrachromosomal DNA (ecDNA) to revolutionize cancer therapeutics.

Nearly 25% of all cancers have gene amplifications, leading to over 400,000 newly diagnosed cases each year in the US alone. Unfortunately, the majority of these patients have limited treatment options and face a poor prognosis. While advancements have been made in treating gene mutations, those with oncogene amplifications have been left behind.

Boundless Bio's groundbreaking science recognizes ecDNA as a key mechanism in cancer development and progression. By targeting this unique vulnerability, we are developing a robust pipeline of ecDNA-directed therapies (ecDTx) to provide effective solutions for patients. Join us on our mission to eliminate cancer cells' reliance on ecDNA and transform the future of cancer treatment